Abstract
Age-related dementias such as Alzheimer disease (AD) have been linked to vascular disorders like hypertension, diabetes and atherosclerosis. These risk factors cause ischemia, inflammation, oxidative damage and consequently reperfusion, which is largely due to reactive oxygen species (ROS) that are believed to induce mitochondrial damage. At higher concentrations, ROS can cause cell injury and death which occurs during the aging process, where oxidative stress is incremented due to an accelerated generation of ROS and a gradual decline in cellular antioxidant defense mechanisms. Neuronal mitochondria are especially vulnerable to oxidative stress due to their role in energy supply and use, causing a cascade of debilitating factors such as the production of giant and/or vulnerable young mitochondrion whos DNA has been compromised. Therefore, mitochondria specific antioxidants such as acetyl-L-carnitine and R-alphalipoic acid seem to be potential treatments for AD. They target the factors that damage mitochondria and reverse its effect, thus eliminating the imbalance seen in energy production and amyloid beta oxidation and making these antioxidants very powerful alternate strategies for the treatment of AD.
Keywords: Alzheimer disease, antioxidants, mitochondria, oxidative stress, reactive oxygen species
CNS & Neurological Disorders - Drug Targets
Title: Mitochondrion-Specific Antioxidants as Drug Treatments for Alzheimer Disease
Volume: 10 Issue: 2
Author(s): Hector H. Palacios, Bharat B. Yendluri, Kalpana Parvathaneni, Vagif B. Shadlinski, Mark E. Obrenovich, Jerzy Leszek, Dmitry Gokhman, Kazimierz Gasiorowski, Valentin Bragin and Gjumrakch Aliev
Affiliation:
Keywords: Alzheimer disease, antioxidants, mitochondria, oxidative stress, reactive oxygen species
Abstract: Age-related dementias such as Alzheimer disease (AD) have been linked to vascular disorders like hypertension, diabetes and atherosclerosis. These risk factors cause ischemia, inflammation, oxidative damage and consequently reperfusion, which is largely due to reactive oxygen species (ROS) that are believed to induce mitochondrial damage. At higher concentrations, ROS can cause cell injury and death which occurs during the aging process, where oxidative stress is incremented due to an accelerated generation of ROS and a gradual decline in cellular antioxidant defense mechanisms. Neuronal mitochondria are especially vulnerable to oxidative stress due to their role in energy supply and use, causing a cascade of debilitating factors such as the production of giant and/or vulnerable young mitochondrion whos DNA has been compromised. Therefore, mitochondria specific antioxidants such as acetyl-L-carnitine and R-alphalipoic acid seem to be potential treatments for AD. They target the factors that damage mitochondria and reverse its effect, thus eliminating the imbalance seen in energy production and amyloid beta oxidation and making these antioxidants very powerful alternate strategies for the treatment of AD.
Export Options
About this article
Cite this article as:
H. Palacios Hector, B. Yendluri Bharat, Parvathaneni Kalpana, B. Shadlinski Vagif, E. Obrenovich Mark, Leszek Jerzy, Gokhman Dmitry, Gasiorowski Kazimierz, Bragin Valentin and Aliev Gjumrakch, Mitochondrion-Specific Antioxidants as Drug Treatments for Alzheimer Disease, CNS & Neurological Disorders - Drug Targets 2011; 10 (2) . https://dx.doi.org/10.2174/187152711794480474
DOI https://dx.doi.org/10.2174/187152711794480474 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antipsychotic Augmentation Strategies to Ameliorate Negative and Cognitive Symptoms in Schizophrenia; Implications for Future Research
Central Nervous System Agents in Medicinal Chemistry Platelets and Platelet Interaction with Progenitor Cells in Vascular Homeostasis and Inflammation
Current Vascular Pharmacology Neurobiological Influences on Recovery from Traumatic Brain Injury: The Role of Genetic Polymorphisms
Current Pharmaceutical Design Central Nervous System Involvement in Pediatric Rheumatic Diseases: Current Concepts in Treatment
Current Pharmaceutical Design A Nanotechnological Approach to the Management of Alzheimer Disease and Type 2 Diabetes
CNS & Neurological Disorders - Drug Targets Immunological Approaches to Prevent Neuronal Apoptosis During Neuroinflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Structure – Function Relationships of Pre-Fibrillar Protein Assemblies in Alzheimers Disease and Related Disorders
Current Alzheimer Research Androgen Therapy in Male Patients Suffering from Type 2 Diabetes: A Review of Benefits and Risks
Current Diabetes Reviews Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward
Current Alzheimer Research Pharmacologic Targeting of Endothelial Progenitor Cells
Cardiovascular & Hematological Disorders-Drug Targets Brain Protection and Cognitive Function: Cocoa Flavonoids as Nutraceuticals
Current Pharmaceutical Design The Role of Adipocytokines in Atherogenesis and Atheroprogression
Current Drug Targets Disrupting β-Amyloid Aggregation for Alzheimer Disease Treatment
Current Topics in Medicinal Chemistry Therapeutic Targets in Prostaglandin E2 Signaling for Neurologic Disease
Current Medicinal Chemistry The Hydrogen Peroxide and its Importance in Alzheimers and Parkinsons Disease
Current Medicinal Chemistry - Central Nervous System Agents Commentary (Research Highlights: Wnt-Signalling: A New Direction for Alzheimer Disease?)
CNS & Neurological Disorders - Drug Targets Pharmacological Activity of Cardiovascular Agents from Herbal Medicine
Cardiovascular & Hematological Agents in Medicinal Chemistry Cardiovascular Pharmacogenetics of Anti-Thrombotic Agents and Non-Steroidal Anti-Inflammatory Drugs
Current Molecular Medicine Neuroprotection for Ischemic Injury in the Immature Brain
Current Pediatric Reviews Motor and Anxiety Effects of PNU-282987, An Alpha7 Nicotinic Receptor Agonist, and Stress in an Animal Model of Alzheimer’s Disease
Current Alzheimer Research